Endoscopic scoring systems for inflammatory bowel disease: pros and cons

References

• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142(1):46-54
   PubMed Web of Science ®Google Scholar
• Burisch J, Jess T, Martinato M, Lakatos PL; ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7(4):322-37
   PubMed Web of Science ®Google Scholar
• Pastorelli L, De Salvo C, Mercado JR, et al. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol 2013;4:280
   PubMed Web of Science ®Google Scholar
• Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013;7(12):982-1018
   PubMed Web of Science ®Google Scholar
• Daperno M, Castiglione F, de Ridder L, et al. Results of the 2nd part Scientific Workshop of the ECCO. II: measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis 2011;5(5):484-98
   PubMed Web of Science ®Google Scholar
• D’Haens G, Feagan B, Colombel JF, et al. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology 2012;143(6):1461-9
   PubMedGoogle Scholar
• Orlando A, Guglielmi FW, Cottone M, et al. Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease. Dig Liver Dis 2013;45(12):986-91
   PubMedGoogle Scholar
• Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61(11):1619-35
   PubMed Web of Science ®Google Scholar
• Meucci G, Fasoli R, Saibeni S, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis 2012;18(6):1006-10
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141(4):1194-201
   PubMed Web of Science ®Google Scholar
• Frøslie KF, Jahnsen J, Moum BA, Vatn MH. IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133(2):412-22
   PubMed Web of Science ®Google Scholar
• Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: a proposed new paradigm for the management of Crohn’s disease. Clin Gastroenterol Hepatol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132(2):763-86
   PubMed Web of Science ®Google Scholar
• Travis SP, Higgins PD, Orchard T, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;34(2):113-24
   PubMed Web of Science ®Google Scholar
• Mazzuoli S, Guglielmi FW, Antonelli E, et al. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis 2013;45(12):969-77
   PubMedGoogle Scholar
• Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7(1):15-29
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2(4947):1041-8
   PubMed Web of Science ®Google Scholar
• Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30(7):983-9
   PubMed Web of Science ®Google Scholar
• Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004;60(4):505-12
   PubMed Web of Science ®Google Scholar
• Sostegni R, Daperno M, Scaglione N, et al. Review article: crohn’s disease: monitoring disease activity. Aliment Pharmacol Ther 2003;17(Suppl 2):11-17
   PubMed Web of Science ®Google Scholar
• Walsh AJ, Ghosh A, Brain AO, et al. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis 2013. [Epub ahead of print]
   Google Scholar
• Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61(4):535-42
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, D’Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013;145(1):149-57
   PubMed Web of Science ®Google Scholar
• Samuel S, Bruining DH, Loftus EV Jr, et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol 2013;11(1):49-54
   PubMed Web of Science ®Google Scholar
• Cooney RM, Warren BF, Altman DG, et al. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials 2007;8:17
   PubMedGoogle Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60(6):780-7
   PubMed Web of Science ®Google Scholar
• Travis SP, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013;145(5):987-95
   PubMed Web of Science ®Google Scholar
• Osada T, Ohkusa T, Yokoyama T, et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: inter- and intraobserver consistency. Inflamm Bowel Dis 2010;16(2):192-7
   PubMedGoogle Scholar
• Sipponen T, Nuutinen H, Turunen U, Färkkilä M. Endoscopic evaluation of Crohn’s disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis 2010;16(12):2131-6
   PubMed Web of Science ®Google Scholar
• Hébuterne X, Lémann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut 2013;62(2):201-8
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Allez M, et al. Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn’s Disease. Clin Gastroenterol Hepatol 2014;12(3):423-31. e1
   PubMed Web of Science ®Google Scholar
• Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142(1):63-70
   PubMed Web of Science ®Google Scholar
• Lémann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology 2005;128(7):1812-18
   PubMed Web of Science ®Google Scholar
• Reinisch W, Rutgeerts P, Panaccione R, et al. Identifying appropriate dichotomizing points for SES-CD to predict long-term clinical remission for adalimumabtreated patients with Crohn’s disease. J Crohns Colitis 2010;4(1):S31-P045
   Google Scholar
• Moskovitz DN, Daperno M, Van assche G, et al. Defining and Validating Cut-Off’s for the Simple Endoscopic Score for Crohn’s Disease. Gastroenterology 2007;132(4):A173-S1097
   Google Scholar
• Ferrante M, Colombel JF, Sandborn WJ, et al. Validation of endoscopic activity scores in patients with Crohn’s disease based on a post hoc analysis of data from SONIC. Gastroenterology 2013;145(5):978-86
   PubMed Web of Science ®Google Scholar
• Ferrante M, Noman M, Vermeire S, et al. Evolution of endoscopic activity scores under placebo therapy in Crohn’s disease. Gastroenterology 2010;138:S358
   Google Scholar
• van der Woude CJ, Stokkers P, van Bodegraven AA, et al. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn’s disease. Inflamm Bowel Dis 2010;16(10):1708-16
   PubMedGoogle Scholar
• Mary JY, Lemann M, Colombel JF, et al. Endoscopic remission and response in Crohn’s disease: an objective definition using the CDEIS. Gut 2005;54:A50
   Google Scholar
• Colombel JF, Lemann M, Bouhnik Y, et al. Endoscopic improvement in patients with active Crohn’s disease treated with certolizumab pegol: first results of the Music clinical trials. Gastroenterology 2010;138:S166
   Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology 2012;142:1102-11
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002;122(2):512-30
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25(6):665-72
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990;99(4):956-63
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology 2004;127(3):730-40
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004;127(3):723-9
   PubMed Web of Science ®Google Scholar
• Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006;55(6):842-7
   PubMedGoogle Scholar
• Reinisch W, Angelberger S, Petritsch W, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn’s disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010;59(6):752-9
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317(26):1625-9
   PubMed Web of Science ®Google Scholar
• Osada T, Ohkusa T, Yokoyama T, et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: inter- and intraobserver consistency. Inflamm Bowel Dis 2010;16(2):192-7
   PubMedGoogle Scholar
• Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964;1(5375):89-92
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352(24):2499-507
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-6
   PubMed Web of Science ®Google Scholar
• Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 2012;18(9):1634-40
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142(2):257-65
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011;9(6):483-9
   PubMed Web of Science ®Google Scholar
• Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98(4):811-18
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 2014;63(1):88-95
   PubMed Web of Science ®Google Scholar
• Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2008;6(11):1218-24
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010;138(2):463-8
   PubMed Web of Science ®Google Scholar
• Thia K, Faubion WA Jr, Loftus et al. Short CDAI: development and validation of a shortened and simplified Crohn’s disease activity index. Inflamm Bowel Dis 2011;17(1):105-11
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease. Dig Dis 2009;27(Suppl 1):80-4
   PubMedGoogle Scholar
• Keohane J, O’Mahony C, O’Mahony L, et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010;105(8):788, 1789-94
   Google Scholar
• Knowles SR, Wilson JL, Connell WR, Kamm MA. Preliminary examination of the relations between disease activity, illness perceptions, coping strategies, and psychological morbidity in Crohn’s disease guided by the common sense model of illness. Inflamm Bowel Dis 2011;17(12):2551-7
   PubMed Web of Science ®Google Scholar
• Papi C, Fascì-Spurio F, Rogai F, et al. Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors. Dig Liver Dis 2013;45(12):978-85
   PubMedGoogle Scholar
• Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140(6):1817-26
   PubMed Web of Science ®Google Scholar
• D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18(12):2218-24
   PubMed Web of Science ®Google Scholar
• Nancey S, Boschetti G, Moussata D, et al. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2013;19(5):1043-52
   PubMed Web of Science ®Google Scholar
• Saibeni S, Rondonotti E, Iozzelli A, et al. Imaging of the small bowel in Crohn’s disease: a review of old and new techniques. World J Gastroenterol 2007;13(24):3279-87
   PubMedGoogle Scholar
• Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 2013;7(7):556-85
   PubMed Web of Science ®Google Scholar
• Panés J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther 2011;34(2):125-45
   PubMed Web of Science ®Google Scholar
• Rimola J, Ordás I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011;17(8):1759-68
   PubMed Web of Science ®Google Scholar
• Ordás I, Rimola J, García-Bosch O, et al. Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. Gut 2013;62(11):1566-72
   PubMedGoogle Scholar
• Calabrese E, Zorzi F, Onali S, et al. Accuracy of small-intestine contrast ultrasonography, compared with computed tomography enteroclysis, in characterizing lesions in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2013;11(8):950-5
   PubMedGoogle Scholar
• Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab Induces Deep Remission in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol 2014;12(3):414-22. e5
   PubMed Web of Science ®Google Scholar
• Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: a proposed new paradigm for the management of Crohn’s disease. Clin Gastroenterol Hepatol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Rogler G, Vavricka S, Schoepfer A, Lakatos PL. Mucosal healing and deep remission: what does it mean? World J Gastroenterol 2013;19(43):7552-60
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO (I): impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011;5(5):477-83
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis 2009;15(9):1295-301
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362(15):1383-95
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006;63(3):433-42
   PubMed Web of Science ®Google Scholar
• Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004;53(12):1813-16
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Kobayashi K, Mukae M, et al. Clinical study of the relation between mucosal healing and long-term outcomes in ulcerative colitis. Gastroenterol Res Pract 2013;2013:192794
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):2462-76
   PubMed Web of Science ®Google Scholar
• Neumann H, Neurath MF. Ulcerative colitis: UCCIS – a reproducible tool to assess mucosal healing. Nat Rev Gastroenterol Hepatol 2012;9(12):692-4
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol 2013. [Epub ahead of print]
   Google Scholar
• Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013;7(10):827-51
   PubMed Web of Science ®Google Scholar
• Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32(2):174-8
   PubMed Web of Science ®Google Scholar
• Mathy C, Schneider K, Chen YY, et al. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis 2003;9(6):351-5
   PubMed Web of Science ®Google Scholar
• Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126(2):451-9
   PubMed Web of Science ®Google Scholar
• Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 2013;11(12):1601-8
   PubMed Web of Science ®Google Scholar
• Gurudu SR, Leighton JA. Correlation of two capsule endoscopy scoring systems with fecal calprotectin: does it really matter? Dig Dis Sci 2012;57:827-9
   PubMedGoogle Scholar
• Bourreille A, Ignjatovic A, Aabakken L, et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 2009;41(7):618-37
   PubMed Web of Science ®Google Scholar
• Tontini GE, Vecchi M, Neurath MF, Neumann H. Advanced endoscopic imaging techniques in Crohn’s disease. J Crohns Colitis 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Mow WS, Lo SK, Targan SR, et al. Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2(1):31-40
   PubMed Web of Science ®Google Scholar
• Gal E, Geller A, Fraser G, et al. Assessment and validation of the new capsule endoscopy Crohn’s disease activity index (CECDAI). Dig Dis Sci 2008;53(7):1933-7
   PubMedGoogle Scholar
• Niv Y, Ilani S, Levi Z, et al. Validation of the Capsule Endoscopy Crohn’s Disease Activity Index (CECDAI or Niv score): a multicenter prospective study. Endoscopy 2012;44(1):21-6
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Defranchis R, Seidman E, et al. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther 2008;27(2):146-54
   PubMed Web of Science ®Google Scholar
• Rosa B, Moreira MJ, Rebelo A, Cotter J. Lewis Score: a useful clinical tool for patients with suspected Crohn’s Disease submitted to capsule endoscopy. J Crohns Colitis 2012;6(6):692-7
   PubMed Web of Science ®Google Scholar
• Swaminath A, Legnani P, Kornbluth A. Video capsule endoscopy in inflammatory bowel disease: past, present, and future redux. Inflamm Bowel Dis 2010;16(7):1254-62
   PubMedGoogle Scholar
• Tontini GE, Vecchi M, Neurath MF, Neumann H. Endoscopic optical enhancement technologies in IBD. EMJ Gastroenterol 2013;1:54-61
   Google Scholar
• Khanna R, Levesque BG, Sandborn WJ. IBD: measuring what counts-endoscopic assessment in IBD. Nat Rev Gastroenterol Hepatol 2014;11(1):9-10
   PubMedGoogle Scholar
• Iacucci M, Panaccione R, Ghosh S. Advances in novel diagnostic endoscopic imaging techniques in inflammatory bowel disease. Inflamm Bowel Dis 2013;19(4):873-80
   PubMedGoogle Scholar
• Neumann H, Mönkemüller K, Neurath MF, et al. Advanced endoscopic imaging. Diagn Ther Endosc 2013;2013:206839
   PubMedGoogle Scholar
• Neumann H, Vieth M, Günther C, et al. Virtual chromoendoscopy for prediction of severity and disease extent in patients with inflammatory bowel disease: a randomized controlled study. Inflamm Bowel Dis 2013;19(9):1935-42
   PubMed Web of Science ®Google Scholar
• Tontini GE, Vecchi M, Neurath MF, Neumann H. Review article: newer optical and digital chromoendoscopy techniques vs. dye-based chromoendoscopy for diagnosis and surveillance in inflammatory bowel disease. Aliment Pharmacol Ther 2013;38(10):1198-208
   PubMed Web of Science ®Google Scholar
• Nishio Y, Ando T, Maeda O, et al. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut 2006;55(12):1768-73
   PubMed Web of Science ®Google Scholar
• Liu J, Dlugosz A, Neumann H. Beyond white light endoscopy: the role of optical biopsy in inflammatory bowel disease. World J Gastroenterol 2013;19(43):7544-51
   PubMed Web of Science ®Google Scholar
• Buda A, Hatem G, Neumann H, et al. Confocal laser endomicroscopy for prediction of disease relapse in ulcerative colitis: a pilot study. J Crohns Colitis 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Neumann H, Kiesslich R, Wallace MB, Neurath MF. Confocal laser endomicroscopy: technical advances and clinical applications. Gastroenterology 2010;139(2):388-92
   PubMed Web of Science ®Google Scholar
• Neumann H, Kiesslich R. Endomicroscopy and endocytoscopy in IBD. Gastrointest Endosc Clin N Am 2013;23(3):695-705
   PubMedGoogle Scholar
• Neumann H, Vieth M, Atreya R, et al. Assessment of Crohn’s disease activity by confocal laser endomicroscopy. Inflamm Bowel Dis 2012;18(12):2261-9
   PubMedGoogle Scholar
• Li CQ, Xie XJ, Yu T, et al. Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy. Am J Gastroenterol 2010;105(6):1391-6
   PubMed Web of Science ®Google Scholar
• Kiesslich R, Duckworth CA, Moussata D, et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 2012;61(8):1146-53
   PubMed Web of Science ®Google Scholar